Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17130472 | 0.94 | EPHX2 (1.00) | EPHX2EPHX1 | |
| SCHEMBL17130360 | 0.94 | EPHX2 (1.00) | EPHX2EPHX1 | |
| SCHEMBL17114602 | 0.88 | EPHX2 (1.00) | EPHX2EPHX1 | |
| SCHEMBL17130395 | 0.87 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL2716978 | 0.87 | EPHX2 (1.00) | EPHX2EPHX1 | |
| SCHEMBL17130481 | 0.86 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL19000774 | 0.84 | EPHX2 (0.76) | EPHX2EPHX1 | |
| SCHEMBL4015613 | 0.82 | EPHX2 (0.77) | EPHX2EPHX1 | |
| SCHEMBL17130484 | 0.81 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL31315639 | 0.81 | EPHX2 (1.00) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112898196-B | Potent soluble epoxide hydrolase inhibitors | 艾科西斯有限责任公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240024302-A1 | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024302-A1 | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023193010-A1 | METHODS OF IMPROVING CANCER IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | disclosed |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | disclosed |
| WO-2022093712-A1 | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-11123311-B2 | Methods of treating mental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | disclosed |
| CN-112898196-A | Potent soluble epoxide hydrolase inhibitors | 艾科西斯有限责任公司 | 2021-06-04 | — | — | CN | disclosed |
| US-20210161881-A1 | METHODS OF INHIBITING FORMATION OF ALPHA SYNUCLEIN AGGREGATES | CHIBA UNIVERSITY (JP) | 2021-06-03 | — | — | US | disclosed |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | disclosed |
| EP-3129023-B1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EICOSIS LLC (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3129023-B1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EICOSIS LLC (US) | 2021-02-24 | — | — | EP | disclosed |
| CN-106163521-B | Potent soluble epoxide hydrolase inhibitors | 艾科西斯有限责任公司 | 2021-02-09 | — | — | CN | disclosed |
| US-10377744-B2 | Potent soluble epdxide hydrolase inhibitors | EICOSIS, LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-10377744-B2 | Potent soluble epdxide hydrolase inhibitors | EICOSIS, LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20170174665-A1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EICOSIS, LLC | 2017-06-22 | — | — | US | disclosed |
| US-20170174665-A1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EICOSIS, LLC | 2017-06-22 | — | — | US | disclosed |
| WO-2015148954-A1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EICOSIS, LLC (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024302-A1 | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY | EPHX1, EPHX2, PTGER1 | EPHX2 2/4885EPHX1 1/4885 |
| US-11723929-B2 | Methods of improving cell-based therapy | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885EPHX1 1/4885 |
| US-20210161881-A1 | METHODS OF INHIBITING FORMATION OF ALPHA SYNUCLEIN AGGREGATES | SNCA, PARK7, PYGB | EPHX2 3967/4885EPHX1 3353/4885 |
| US-10377744-B2 | Potent soluble epdxide hydrolase inhibitors | EPHX1, EPHX2, LTA4H | EPHX2 2/4885EPHX1 1/4885 |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | EPHX2 4/4885EPHX1 2/4885 |
| US-11123311-B2 | Methods of treating mental disorders | FAAH, EPHX1, FAAH2 | EPHX2 4/4885EPHX1 2/4885 |
| US-20170174665-A1 | POTENT SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, LTA4H | EPHX2 2/4885EPHX1 1/4885 |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885EPHX1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.